Cargando…
Rivaroxaban treatment for cancer-associated venous thromboembolism in a patient with heparin-induced thrombocytopenia: a case report
Low molecular weight heparin (LMWH) is the first-line therapy in acute cancer-associated venous thromboembolism (CAT). However, heparin-induced thrombocytopenia (HIT) is a life-threatening adverse drug reaction that occurs in anticoagulation therapy with LMWH. This article reports the case of a 66-y...
Autores principales: | Le, Ke-Jia, Yan, Yi-Dan, Liu, Yang-Xi, Xu, Jia-Bo, Cui, Min, Gu, Zhi-Chun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797388/ https://www.ncbi.nlm.nih.gov/pubmed/35117000 http://dx.doi.org/10.21037/tcr.2019.09.55 |
Ejemplares similares
-
Rivaroxaban for cancer-associated venous thromboembolism
por: Liang, Bo, et al.
Publicado: (2021) -
Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer
por: Lee, Jang Ho, et al.
Publicado: (2019) -
Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2023) -
Can rivaroxaban be a drug of choice for treating heparin-induced thrombocytopenia in a patient with pulmonary thromboembolism?
por: Vavlukis, Marija, et al.
Publicado: (2017) -
Apixaban/heparin/rivaroxaban: Melaena and thrombocytopenia: 2 case reports
Publicado: (2020)